Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some claims are supported by the provided label excerpts (e.g., atorvastatin CYP3A4 metabolism; myopathy/rhabdomyolysis; temporary withholding for serious myopathy risk; liver test timing). Several other claims are not supported by the provided label text (e.g., loop diuretic effects on muscle tissue/electrolytes, specific monitoring patterns like CK/electrolyte panels, renal effects and creatinine/ALT/AST monitoring frequency, and off-label-like management choices). Claims about generic availability, patent-tracking, and cost are not addressed in the label excerpts.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is metabolized by CYP3A4.
12.3 Pharmacokinetics: “LIPITOR is metabolized… by cytochrome P450 3A4…”
Lipitor occasionally causes myopathy.
5.1 Skeletal Muscle: “Atorvastatin… occasionally causes myopathy…”
Lipitor rarely causes rhabdomyolysis.
5.1 Skeletal Muscle: “Rare cases of rhabdomyolysis…”
Lipitor therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a myopathy or having a risk factor predisposing to renal failure secondary to rhabdomyolysis.
5.1 Skeletal Muscle: “LIPITOR therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a myopathy…”
It is recommended that liver function tests be performed prior to and at 12 weeks following initiation of therapy and any elevation of dose.
5.2 Liver Dysfunction: “It is recommended that liver function tests be performed prior to and at 12 weeks following both the initiation of therapy and any elevation of dose…”
The risk of myopathy during statin treatment is increased with concurrent administration of cyclosporine or strong CYP 3A4 inhibitors.
7 Drug Interactions: “The risk of myopathy during treatment with statins is increased with concurrent administration of… cyclosporine, or strong CYP 3A4 inhibitors…”
Risk of hemorrhagic stroke is higher in the LIPITOR 80 mg group vs placebo in a post-hoc analysis.
5.5 Use in Patients with Recent Stroke or TIA: “a higher incidence of hemorrhagic stroke was seen in the LIPITOR 80 mg group compared to placebo…”
Unsupported Statements
Lipitor (atorvastatin) and loop diuretics like furosemide or torsemide have no major pharmacokinetic interaction.
Provided label excerpts do not discuss loop diuretics (furosemide/torsemide) or any pharmacokinetic interaction with atorvastatin.
Lipitor does not significantly alter loop diuretics’ blood levels due to lack of significant pharmacokinetic interaction.
No label support in provided excerpts addressing loop diuretic blood levels or atorvastatin effects on them.
Loop diuretics do not significantly alter Lipitor’s blood levels due to lack of significant pharmacokinetic interaction.
No label support in provided excerpts addressing loop diuretics affecting atorvastatin plasma concentrations.
Loop diuretics like furosemide or torsemide are eliminated by renal excretion.
No label support in provided excerpts for loop diuretic pharmacokinetics.
Both Lipitor and loop diuretics can affect muscle tissue.
Label excerpts discuss skeletal muscle effects for atorvastatin only; no loop diuretic muscle effects are discussed.
Lipitor alone increases the chance of myopathy.
Label states atorvastatin occasionally causes myopathy and that risk increases with higher doses and certain concomitant drugs; it does not support the phrasing that atorvastatin “alone” increases the chance of myopathy.
Loop diuretics lower potassium.
No label support in provided excerpts regarding loop diuretic effects on electrolytes.
Loop diuretics lower magnesium.
No label support in provided excerpts regarding loop diuretic effects on electrolytes.
Electrolyte reductions from loop diuretics can worsen statin-related muscle pain or weakness.
No label support tying loop diuretic electrolyte changes to worsening statin muscle symptoms.
When patients report unexplained soreness while taking these drugs, clinicians often check creatine kinase.
No label support in provided excerpts for creatine kinase monitoring practices.
When patients report unexplained soreness while taking these drugs, clinicians often check electrolyte panels.
No label support in provided excerpts for electrolyte panel monitoring in this context.
Clinicians may adjust doses or temporarily stop one agent when these symptoms occur.
Label supports temporarily withholding or discontinuing LIPITOR in certain myopathy situations, but does not support dose adjustment/temporary stopping of “one agent” broadly or any specific loop diuretic management.
Loop diuretics can reduce kidney function in volume-depleted patients.
No label support in provided excerpts for loop diuretic renal effects.
Lipitor can occasionally elevate liver enzymes.
Label excerpt includes liver enzyme abnormalities and persistent transaminase elevations; it does not specifically support “occasionally elevate liver enzymes” as phrased.
Combined use prompts more frequent checks of serum creatinine.
No label support for creatinine or serum creatinine monitoring frequency in provided excerpts.
Combined use prompts more frequent checks of ALT.
Label provides general recommendation for liver function tests prior to and at 12 weeks after initiation and after dose increases, but does not support “more frequent” ALT checks due to combined use.
Combined use prompts more frequent checks of AST.
Same issue as ALT: no provided support for AST-specific or more frequent monitoring due to combined use.
More frequent liver enzyme and kidney monitoring is especially done in the first few months or after dose increases.
Label only specifies liver function tests prior to and at 12 weeks following initiation and any elevation of dose; it does not mention kidney monitoring frequency or a “first few months” timeframe beyond the 12-week statement.
Problems surface mainly in older adults.
No label support in provided excerpts for age being the main determinant of problems.
Problems surface mainly in patients with chronic kidney disease.
No label support in provided excerpts identifying CKD as the main group for these problems.
Problems surface mainly in patients taking multiple interacting drugs such as clarithromycin.
No label support in provided excerpts mentioning clarithromycin or that it is a main driver in this manner.
Problems surface mainly in patients taking multiple interacting drugs such as cyclosporine.
Label supports that cyclosporine increases risk of myopathy, but does not support the statement that problems surface “mainly” in those patients.
In these higher-risk groups, clinicians may choose a lower statin dose.
Provided label excerpts do not discuss lowering atorvastatin dose as a management recommendation for those risk groups.
In these higher-risk groups, clinicians may switch to a hydrophilic statin like rosuvastatin.
No label support in provided excerpts for switching to rosuvastatin or to hydrophilic statins.
In these higher-risk groups, clinicians may add potassium-sparing agents to offset electrolyte losses.
No label support in provided excerpts for adding potassium-sparing agents or for electrolyte-loss offsetting as management.
Both Lipitor and common loop diuretics are off-patent.
Label excerpts do not address patent status.
Both atorvastatin and common loop diuretics are widely available as low-cost generics.
Label excerpts do not address generic availability or cost.
Cost does not limit the choice of one over another.
Label excerpts do not address cost or prescribing decision factors.
DrugPatentWatch.com tracks remaining formulation or method-of-use patents that occasionally surface for specific extended-release versions.
Label excerpts do not address any patent-tracking sources or extended-release versions.
These patent-related issues rarely affect routine co-prescription.
Label excerpts do not address patent issues or routine co-prescription.
Contradictions
Low
AI Statement
Lipitor (atorvastatin) and loop diuretics like furosemide or torsemide have no major pharmacokinetic interaction.
Label Reference
7 Drug Interactions and other provided excerpts do not confirm absence of interaction with loop diuretics.
Important Omissions
No discussion of LIPITOR contraindications relevant to safety (active liver disease; hypersensitivity; pregnancy/breastfeeding contraindications).
Importance:
Moderate
No on-label indication, population, or dosage regimen details for LIPITOR (e.g., starting dose, dose range, administration timing).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple claims about loop diuretics (pharmacokinetic interaction absence, electrolyte changes, monitoring practices) are unsupported by the provided label excerpts. While atorvastatin-specific safety points (myopathy/rhabdomyolysis, temporary withholding, liver test timing) include some supported statements, the overall set includes several management/monitoring assertions not grounded in the provided label text, which could mislead safety monitoring decisions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Many statements are not supported by the provided FDA label excerpts, especially those involving loop diuretics’ interactions, electrolyte effects, renal outcomes, and specific monitoring/management behaviors.
Suggested Improvement
Limit claims to label-supported atorvastatin statements from the provided excerpts (e.g., CYP3A4 metabolism; skeletal muscle and liver warning framework; interaction risk with cyclosporine/strong CYP3A4 inhibitors; liver function test timing) and remove or qualify loop-diuretic-specific interaction/monitoring assertions not present in the supplied label text.